Trials / Completed
CompletedNCT00979056
Prophylactic Treatment of Travellers' Diarrhoea With Rifaximin
Prospective, Randomised, Placebo Controlled, Double Blind Monocenter Trial for the Prophylactic Treatment of Diarrhoea With Rifaximin for Travellers to South- and Southeast-Asia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 258 (actual)
- Sponsor
- Dr. Philipp Zanger, MD MSc DTM · Academic / Other
- Sex
- All
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Accepted
Summary
The aim of the study is to investigate the efficacy of the prophylactic treatment with rifaximin to prevent travellers diarrhoea.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rifaximin | 400 mg per day, oral use, maximum duration 28 days |
| DRUG | Lactose | Coated Tablet, Oral Use |
Timeline
- Start date
- 2009-10-01
- Primary completion
- 2012-03-01
- Completion
- 2012-10-01
- First posted
- 2009-09-17
- Last updated
- 2013-11-08
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00979056. Inclusion in this directory is not an endorsement.